The Impact of Pulmonary Hydatid Cyst Rupture on COVID-19 Symptom Severity

Acta Parasitol. 2024 Mar;69(1):1090-1094. doi: 10.1007/s11686-024-00803-4. Epub 2024 Mar 17.

Abstract

Background: Co-infection with other microorganisms such as parasites in patients with COVID-19 can affect the clinical outcome and require prompt diagnosis and appropriate therapy.

Case presentation: We present a case of an adult male with chest pain, dyspnea, cough, diplopia, and anorexia who was confirmed to have acute COVID-19 pneumonia. 2 weeks prior to admission, a hydatid lung cyst was identified on examination, but the patient refused surgery. Thoracoabdominal computed tomography (CT) revealed a rupture of the lung hydatid cyst and co-infection with COVID-19. The patient has prescribed a treatment protocol for COVID-19 and albendazole. Despite measures taken to manage severe inflammation and decreasing blood oxygen levels, the patient required admission to the intensive care unit (ICU) and intubation. After approximately 3 weeks of hospitalization, the patient was successfully extubated and discharged uneventfully from the hospital. Oral albendazole was prescribed for follow-up treatment.

Conclusion: Our case highlights the importance of considering hydatid cysts in the differential diagnosis of patients with COVID-19, especially those living in endemic areas.

Keywords: COVID-19; Co-infection; Pulmonary hydatid disease; Rupture.

Publication types

  • Case Reports

MeSH terms

  • Albendazole* / administration & dosage
  • Albendazole* / therapeutic use
  • COVID-19* / complications
  • COVID-19* / diagnosis
  • Coinfection / diagnosis
  • Coinfection / parasitology
  • Echinococcosis, Pulmonary* / complications
  • Echinococcosis, Pulmonary* / diagnosis
  • Echinococcosis, Pulmonary* / diagnostic imaging
  • Humans
  • Lung / diagnostic imaging
  • Lung / parasitology
  • Lung / pathology
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Severity of Illness Index
  • Tomography, X-Ray Computed

Substances

  • Albendazole